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Antiretroviral therapy has changed the course of HIV disease and improved quality of life in HIV patients. Incidence of an oral
lichenoid drug reaction induced by zidovudine is not common. Once it occurs, it aﬀects a patient’s well being, in particular their
oral functions. Here we report the ﬁrst case of a 34-year-old Thai man with painful erosive lesions involving the lip and buccal
mucosa. Treatment with topical ﬂuocinolone acetonide 0.1% alleviated the patient’s oral pain, but it was not until the subsequent
withdrawal of zidovudine that the patient showed improvement and resolution of the lesions. Long-term follow-up was useful in
the management of this patient, and no recurrence of the lesion was found during 21-month follow-up in this patient.
1.Introduction
Oral lichenoid drug reaction (OLDR) is not an infrequent
occurrencefollowinginitiationofcertaindrugregimenssuch
as antihypertensive and antiretroviral medications. OLDR
lesions clinically present as white striae, papules, plaques
with erythema, or erosion of the oral mucosa. The severity
of symptoms can vary from burning sensation to severe
pain interfering with a patient’s oral functions. OLDR is
diﬃcult to distinguish clinically, with identical presentation
in biopsies, from oral lichen planus (OLP). A thorough
medical history, especially medications taken and distinct
clinical appearance with subsequent resolution following
drugcessationareessentialinanaccuratediagnosisofOLDR
[1].
HIV-infected patients who commence on antiretrovirals
need life-long treatment. The antiretrovirals (ARVs) reduce
viral load and increase CD4+ T cell count thereby slowing
disease progression and improving the patients’ quality of
life [2]. Since the approval of AZT by the US FDA in
1987, it has been widely used for the treatment of human
immunodeﬁciency virus infection. In Thailand, highly active
antiretroviral therapy (HAART) is usually composed of
zidovudine (AZT) or stavudine (d4T) + lamivudine (3TC)
plus nevirapine (NVP) or efavirenz (EFV) [3]. During the
course of ARVs administration, the patients may experience
adverse drug eﬀects [4–6]. The orofacial adverse eﬀects
of HAART including oral ulcers, xerostomia, mucositis,
hyperpigmentation, erythema multiforme (EM), cheilitis,
perioral paresthesia, angioedema, and taste alteration have
beenreported[7].Toourknowledge,therehasbeenonlyone
report of AZT-induced lichenoid reaction [8]. In this report,
we describe the ﬁrst Thai HIV patient presenting with oral
lichenoid drug reaction after receiving HAART containing
AZT which resolved following drug removal.
2.CaseReport
A 34-year-old man was referred to the Faculty of Den-
tistry, Chulalongkorn University, Bangkok, Thailand from2 International Journal of Dentistry
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Figure 1: The time line of drug administration, occurrence of the oral lesions, withdrawal of the AZT, and remission of the lesions.
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Figure 2: The oral lesions at the ﬁrst visit: (a) right buccal mucosa, score 5, (b) left buccal mucosa, score 5, and (c) lip, score 4. Note the
white striae and papules with deep ulceration on the erythematous base.
the Department of Medicine, King Chulalongkorn Memorial
Hospital with a chief complaint of a painful and burning
sensation of lip and oral mucosa when consuming food.
The patient was an ex-intravenous drug user who had
acquired HIV and hepatitis C (HCV) genotype 1 infections
for 12 years possibly from multiple heterosexual partners or
intravenous drug use. He had tuberculosis (TB) of lymph
gland and had been treated with anti-TB drugs for one year.
Six months after the TB treatment, HAART was started with
daily doses of 600mg AZT, 300mg 3TC, and 800mg of
EFV. Monitoring of drug eﬃcacy was assessed periodically.
Baseline plasma HIV-1 RNA viral load (VL) was 97,500
copies per mL (4.99log) before commencing HAART. He
responded quite well to the treatment and the HIV-VL fell
below the limit of detection of less than 50 copies per mL
after6monthsoftreatment.Thepatient’simmunestatuswas
improved with the absolute CD4+ T cell count at baseline,
6 months, and 30 months as 31, 168, and 287 cells per μL,
respectively.
The patient denied drug hypersensitivity, smoking, and
alcohol consuming habits. The oral lesions developed two
and a half years after beginning HAART. Oral examination
revealed erosive lesions of the lip and right and left sides
of buccal mucosa. The lesions had slightly raised keratotic
white reticular striae and white papules on an extensive
background of erythematous mucosa with deep ulcerations
(Figures 2(a), 2(b),a n d2(c)). Clinical scores of the right and
left buccal mucosa as well as the lip lesions were 5, 5, and
4, respectively [9]. Both lateral sides of the tongue displayed
nonpainful and very mild white plaques. Areas of redness
corresponding to the sharp edges of the adjacent teeth were
also observed. The OLDR diagnosis of lesions at the lip and
buccal mucosa was based on the history of medications and
the incidence of initial eruptions of the lesions as shown
in Figure 1. Management in this patient was focused on
relievingthesymptoms.Topicalﬂuocinoloneacetonide0.1%
orabase, solution, and sodium bicarbonate mouthwash were
prescribed. Smoothing of sharp edges area of teeth resolvedInternational Journal of Dentistry 3
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Figure 3: Oral lesions improved at 21 months: (a) right buccal mucosa, score 1, (b) left buccal mucosa, score 0, and (c) the lip, score 0.
in healing of the red area at lateral sides of the tongue,
and long-term follow-up was planned. While the use of
topical steroid relieved the patient of oral pain, the lesions
themselves did not resolve. After treating the oral lesions
for 19 months, a liver biopsy was performed and showed
ﬁbrosis stage 3 from chronic HCV type 1 hepatitis. Pegylated
interferon and ribavirin were planned to be prescribed to the
patient in management of the HCV infection. Due to the
myelosuppressive eﬀect of AZT, it was decided to withdraw
the patient from AZT prior to interferon administration.
AZT was switched to tenofovir (TDF) 300mg, but EFV and
3TC were continued. Two months after the withdrawal of
AZT and with the local topical steroid treatment, only very
mild white papules at right buccal mucosa remained, and the
clinical pain score at this site was 1, while other sites were
in complete remission (Figure 3). Pegylated interferon and
ribavirin therapy began 1 year after the cessation of AZT.
3. Discussion
Here we report the ﬁrst case of a 34-year-old Thai HIV
positive man receiving HAART (AZT, 3TC, and EFV),
presenting with painful erosive lesions involving the lip and
buccal mucosa. While topical steroid application lessened
his pain, it was only upon removal of AZT from his drug
regimen with all other factors constant that his lesions
improved, indicating a diagnosis of OLDR.
OLDR induced by AZT is possibly caused by the CD8+
T cells previously primed from previous antigens. CD8+ T
cells become trapped and persist at the mucosal site, and
laterbecomeeﬀectorsofmucosaldamageaftercross-reacting
with the drug [10].
Histopathological study is one method used to conﬁrm
the OLDR diagnosis, but it was not possible in this case
since the patient refused a biopsy. However, the diagnosis
was based on a thorough history of medications taken, and
a typical oral presentation, with lesions resolving subsequent
to cessation of the drug. AZT-induced OLDR was previously
reported in 8 cases since the introduction of this drug in
treating HIV patients by Ficarra [8]. Xerostomia and EM
can be found in patients taking 3TC and EFV [7], while
mucocutaneous hyperpigmentation and EM are common
orofacial eﬀects of AZT [7]. EM was easily excluded because
EM usually has an acute onset, while in this patient the onset
was over 2 years after HAART began. Furthermore, obvious
Wickham’s striae were observed in the lesions. Although
hairy leukoplakia (HL) was detected at the lateral sides of
the tongue in this patient, the lesions at the lip and buccal
mucosa could be easily discriminated from HL by the clinical
characteristics of reticular raised white striae.
The relationship between OLP and hepatitis C virus
(HCV) infection has been reported in Thai patients with
OLP [11]. A thorough medical history and a long-term
follow-up showed the oral lesions remitted around the
time the patient was withdrawn from AZT. The treatment
of HCV infection with pegylated interferon and ribavirin
began 9 months after the remission of oral lesions; so it is
quite unlikely that these played a role in this case. Candida
infection and smoking related leukoplakia were also in the
diﬀerential diagnosis but were ruled out. Hyperkeratotic
lesions caused by human papilloma virus (HPV) were also
excluded because HPV infection normally displays as either
multiplesessileordome-shapelesionsdependingonthetype
of HPV, but without ulceration. Furthermore, there was a
remission of the lesions after discontinuing the drug.
Various drugs have been reported to cause lichenoid
reaction, including isoniazid, one of the antituberculosis
drugs [12], but the OLDR did not develop until 2 years after
the withdrawal of isoniazid in this patient. Ficarra reported
that OLDR developed 8–24 weeks after the initiation of AZT
or ketoconazole [8]. In this case, OLDR lesions appeared
2.5 years after initiation of the HAART. OLDR was seen to
develop after administration of drugs varied from 1 month
to a year in one study [13]. In our case, remission resulted
two months after the withdrawal of AZT. In OLDR it is
common to observe improvement of the lesions at least
a month after withdrawal of the suspected drug [14, 15].
To determine with absolute certainty that AZT was the
cause of this patient’s lesions would require rechallenge,
or provocation with the drug. The ethics of such a course
of action are extremely questionable, given the severity of
this patient’s lesions. Treatment with topical ﬂuocinolone
acetonide 0.1% alleviated the patient’s oral pain, but it
was not until the subsequent withdrawal of zidovudine
that the patient showed improvement and resolution of the
lesions.4 International Journal of Dentistry
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